Inventor
PARIKH BHAVNISH
US18 patents
⚠️ This page may combine multiple inventors who share the name “PARIKH BHAVNISH”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
INCYTE CORP
17 patentsUS10166191B2Jan 1, 2019
Sustained-release dosage forms of ruxolitinib
INCYTE CORP32 citations97
US9655854B2May 23, 2017
Sustained release dosage forms for a JAK1 inhibitor
INCYTE CORP55 citations95
US11219624B2Jan 11, 2022
Topical formulation for a JAK inhibitor
INCYTE CORP10 citations94
US10758543B2Sep 1, 2020
Topical formulation for a JAK inhibitor
INCYTE CORP14 citations94
US11337927B2May 24, 2022
Sustained-release dosage forms of ruxolitinib
INCYTE CORP12 citations93
US10874616B2Dec 29, 2020
Sustained-release dosage forms of ruxolitinib
INCYTE CORP17 citations93
US10869870B2Dec 22, 2020
Topical formulation for a JAK inhibitor
INCYTE CORP10 citations92
US10561616B2Feb 18, 2020
Sustained release dosage forms for a JAK1 inhibitor
INCYTE CORP15 citations92
US11045421B2Jun 29, 2021
Sustained release dosage forms for a JAK1 inhibitor
INCYTE CORP11 citations83
US11590136B2Feb 28, 2023
Topical formulation for a JAK inhibitor
INCYTE CORP2 citations73
US11571425B2Feb 7, 2023
Topical formulation for a JAK inhibitor
INCYTE CORP2 citations73
US12564593B2Mar 3, 2026
Topical formulation for a JAK inhibitor
INCYTE CORP0 citations62
US12544381B2Feb 10, 2026
Topical formulation for JAK inhibitor
INCYTE CORP0 citations62
US11896717B2Feb 13, 2024
Sustained-release dosage forms of ruxolitinib
INCYTE CORP0 citations62
US11576864B2Feb 14, 2023
Sustained-release dosage forms of ruxolitinib
INCYTE CORP0 citations62
US11576865B2Feb 14, 2023
Sustained-release dosage forms of ruxolitinib
INCYTE CORP0 citations62
US12151026B2Nov 26, 2024
Sustained release dosage forms for a JAK1 inhibitor
INCYTE CORP0 citations60